secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rallybio Corp (RLYB)
CIK:        0001739410
Form:       8-K
Filed at:   2024-03-12T23:59:59+00:00
Accession:  0001739410-24-000030
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rallybio reports Q4 net loss $20.2M, cash $109.9M; workforce cut 45%, Phase 2 RLYB212 on track
--------------------------------------------------------------------------------

- Net loss Q4 2023 $20.2M ($0.50/sh); full year loss $74.6M ($1.84/sh).
- Cash, equivalents, marketable securities $109.9M at Dec 31, 2023; runway into mid-2026 after 45% workforce reduction.
- EMA protocol assistance feedback received for RLYB212; Phase 2 FNAIT study expected to start 2H 2024.
- RLYB116 Phase 1 multiple dose showed >93% free C5 reduction; manufacturing enhancements to enable higher doses.
- R&D expenses $53.5M (up 31% YoY); G&A $25.4M (down 7% YoY).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739410/000173941024000030/0001739410-24-000030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739410/000173941024000030/rlyb-20240312.htm
  HTML page:      https://secwatch.observer/filing/0001739410-24-000030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer